NTM Elite agar
Selective isolation of Non-Tuberculous Mycobacterium
NTM Elite agar is an innovative selective medium for isolation of Non-Tuberculous Mycobacterium (NTM) from respiratory specimens, including Cystic Fibrosis patient samples
- High fertility and selectivity
- No decontamination phase
- Usable in routine microbiology laboratories
For More
Information
Widely present in the environment, Non-Tuberculous Mycobacteria (NTM) are opportunistic pathogens that can cause chronic pulmonary diseases. M.abscessus and M.avium complex are the most frequently encountered species in pulmonary infections. Associated with progressive lung damage, M.abscessus is also the most drug-resistant mycobacterium, extremely challenging to treat.(1)
In patients suffering from Cystic Fibrosis, Chronic Obstructive Pulmonary Disease or Bronchiectasis, accurate diagnosis of NTM infection is essential to help clinicians target the right treatment and implement appropriate measures. Annual screening is now highly recommended, and regular follow-up is needed in positive cases.(2)
Designed for selective culture of NTM, the NTM Elite agar plate is the industrial version of the RGM medium. It enables easier and improved diagnosis compared to commonly used Acid-Fast Bacilli (AFB) culture media.
Improved workflow and accuracy
- No prior decontamination needed
- High selectivity: 85.6% versus 18.6%*
- Drastically improved fertility: 95% versus 40%*
- Incubation at 30°C enhances growth of NTM without allowing growth of BSL3** mycobacteria
- Usable in routine BSL2** microbiology laboratories
* compared to AFB reference method: Lowenstein Jensen medium associated with MGIT medium
** BSL: BioSafety Level
Easy reading
(1)Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.
Larsson, L. O., E. Polverino, W. Hoefsloot, L. R. Codecasa, R. Diel, S. G. Jenkins and M. R. Loebinger
Expert Rev Respir Med 2017 11(12): 977-989.
PubMed link: https://www.ncbi.nlm.nih.gov/pubmed/28967797
Journal site link : https://www.tandfonline.com/doi/abstract/10.1080/17476348.2017.1386563
(2)US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.
Floto, R. A., K. N. Olivier, L. Saiman, C. L. Daley, J. L. Herrmann, J. A. Nick, P. G. Noone, D. Bilton, P. Corris, R. L. Gibson, S. E. Hempstead, K. Koetz, K. A. Sabadosa, I. Sermet-Gaudelus, A. R. Smyth, J. van Ingen, R. J. Wallace, K. L. Winthrop, B. C. Marshall and C. S. Haworth
Thorax 2016 71 Suppl 1: i1-22.
PubMed link: https://www.ncbi.nlm.nih.gov/pubmed/26666259
Journal site link: https://thorax.bmj.com/content/71/Suppl_1/i1.long
Please consult your local bioMérieux representative for product availability
NTM Elite agar | ||
---|---|---|
Ref. 423144 | 20 plates x 90 mm |
Please consult your local bioMérieux representative for product availability
Please consult your local bioMérieux representative for product availability
PRN# 059746 Rev 0.1A